RDAF welcomes new board members in 2019

    26 Mar, 2019

    In March 2019, the General Assembly of the Rare Disease Action Forum (RDAF) elected the Forum’s board, welcoming two new board members: Dr. Pierre Morneau, General Manager at Takeda Switzerland and Dr. Saskia Karg, Project Lead Rare Diseases at the University Children’s Hospital Zürich.

    The two new board members succeed Ms Rute Fernandes, General Manager at Takeda Switzerland and Matthias Heck, Director Global Value, Access and Policy at Alexion who did not run for reelection. The secretariat would like to thank Rute Fernandes and Matthias Heck for the considerable expertise and great contributions made as a board members of the RDAF. The new board composition reaffirms the multistakeholder approach of the Forum. The RDAF is looking forward to continuing its efforts to facilitate the development of sustainable solutions that improve the situation of patients with rare diseases in Switzerland.

    Continue reading

    Joint statement on the KVV/OAMal and KLV/OPAS revision

    The RDAF co-signed a joint statement with other stakeholders on the revision of the Health Insurance Ordinance (KVV/OAMal) and Health Benefits Ordinance (KLV/OPAS). The statement highlights the potential negative impacts of the revision, including the following: -...